Tonix Pharma (TNXP) Misses Q4 EPS by 586c

Tonix Pharma (NASDAQ: TNXP) reported Q4 EPS of ($9.77), $5.86 worse than the analyst estimate of ($3.91). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $3.2 million.

For earnings history and earnings-related data on Tonix Pharma (TNXP) click here.

You May Also Be Interested In

• Goldman Sachs Reiterates Conviction Buy Rating on Golar LNG Ltd. (GLNG)
• Erste Group Reiterates Hold Rating on Broadcom Limited (AVGO)
• Asana (ASAN) Reiterated at Market Outperform by Citizens Post Investor Meet